After numerous investigations on the large individual differences among patients in terms of treatment outcomes of ICIs, a series of biomarkers have been identified particularly for solid tumors, including clinical features (e.g., age and gender), tumoral characteristics (e.g., tumor mutation burden and PD-L1 expression) (Yan et al., 2018; Havel et al., 2019). The gene discussed is CD274; the disease is neoplasm.